Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Miami UAdapt Trial
NCT06111313Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Nov 2024
- Primary completion
- Nov 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tissue-plasminogen activator in prostate cancer (PCa) (4 arms), sponsored by University of Miami. Primary endpoints: Proportion of Patients with Biochemical Disease Failure (FFBN9mo) at 14 months and Proportion of Patients with Clinical Disease Failure at 14 months. Started Nov 2024; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06111313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111313.